ArticleExtracellular vesicle2025
MicroRNAs won the Nobel Prize. Now, can extracellular vesicles help them become drugs?
Article in Extracellular vesicle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Gelatin/Lignin Hydrogel Loaded with Mesenchymal Stem Cell-Derived Exosomes Enriched in Microrna-185 Inhibits Progression of Oral Cancer.Pharmaceutics · 2026Article
- Review
- The dynamic interplay between viruses and host non-coding RNA species.FEMS microbiology reviews · 2026Review
- Small RNAs, big impact: microRNAs in malaria pathogenesis, therapeutic opportunities, and challenges.Frontiers in cellular and infection microbiology · 2026Review
- Extracellular vesicles delivering TIMP-2 modulate MMP-1, MMP-2, and MMP-9 expression in human lung adenocarcinoma A549 cells.Frontiers in pharmacology · 2026Article
- Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The 2024 Nobel Prize recognized microRNAs (miRNAs) as transformative regulators of gene expression. However, their clinical potential has been constrained by instability and delivery challenges. Extracellular vesicles (EVs), as natural carriers of miRNAs, address these limitations by protecting miRNAs from degradation and enabling their precise targeting. As such, harnessing EVs for miRNA delivery has the potential to redefine therapeutic approaches and offer innovative strategies to tackle the most challenging diseases of the 21st century. In this perspective, we examine the advantages and hurdles of EV-mediated miRNA delivery, from state-of-the-art research to its path toward commercialization. This article aims to inspire readers with the promise of EVs and miRNAs as revolutionary tools for future medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.